IgE-associated allergic disorders: recent advances in etiology, diagnosis, and treatment

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 71, Issue 12, 2016, Pages 1652-1661

  Zellweger, F ^a,b   Eggel, A ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

diagnosis; IgE; IgE associated allergic diseases; prevention; therapy

Indexed keywords

ALLERGEN; CYTOKINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY;

ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC RHINITIS; ATOPIC DERMATITIS; FOOD ALLERGY; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; MULTICENTER STUDY (TOPIC); NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN ALLERGY; SYSTEMATIC REVIEW (TOPIC); URTICARIA; CLINICAL TRIAL (TOPIC); DISEASE MANAGEMENT; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOLOGY;

CLINICAL TRIALS AS TOPIC; DISEASE MANAGEMENT; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E;

EID: 84995609114     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.13059     Document Type: Review

References (89)

1. Anandan C, Nurmatov U, van Schayck OCP, Sheikh A. Is the prevalence of asthma declining? Systematic review of epidemiological studies. Allergy 2010;65:152–167.
2. de Korte-de Boer D, Mommers M, Gielkens-Sijstermans CML, Creemers HMH, Mujakovic S, Feron FJM et al. Stabilizing prevalence trends of eczema, asthma and rhinoconjunctivitis in Dutch schoolchildren (2001–2010). Allergy 2015;70:1669–1673.
3. Ballardini N, Bergström A, Wahlgren C-F, van Hage M, Hallner E, Kull I et al. IgE antibodies in relation to prevalence and multimorbidity of eczema, asthma, and rhinitis from birth to adolescence. Allergy 2015;71:342–349.
4. Casas L, Sunyer J, Tischer C, Gehring U, Wickman M, Garcia-Esteban R et al. Early-life house dust mite allergens, childhood mite sensitization, and respiratory outcomes. Allergy 2015;70:820–827.
5. Olivieri M, Heinrich J, Schlünssen V, Antó JM, Forsberg B, Janson C et al. The risk of respiratory symptoms on allergen exposure increases with increasing specific IgE levels. Allergy 2016;71:859–868.
6. Vandenplas O, Froidure A, Meurer U, Rihs HP, Rifflart C, Soetaert S et al. The role of allergen components for the diagnosis of latex-induced occupational asthma. Allergy 2016;71:840–849.
7. Beckhaus AA, Garcia-Marcos L, Forno E, Pacheco-Gonzalez RM, Celedón JC, Castro-Rodriguez JA. Maternal nutrition during pregnancy and risk of asthma, wheeze, and atopic diseases during childhood: a systematic review and meta-analysis. Allergy 2015;70:1588–1604.
8. Kivistö JE, Protudjer JLP, Karjalainen J, Wickman M, Bergström A, Mattila VM. Hospitalizations due to allergic reactions in Finnish and Swedish children during 1999–2011. Allergy 2016;71:677–683.
9. Ferro MA, Van Lieshout RJ, Ohayon J, Scott JG. Emotional and behavioral problems in adolescents and young adults with food allergy. Allergy 2016;71:532–540.
10. Pastor-Vargas C, Maroto AS, Díaz-Perales A, Villaba M, Casillas Diaz N, Vivanco F et al. Sensitive detection of major food allergens in breast milk: first gateway for allergenic contact during breastfeeding. Allergy 2015;70:1024–1027.
11. Burney PGJ, Potts J, Kummeling I, Mills ENC, Clausen M, Dubakiene R et al. The prevalence and distribution of food sensitization in European adults. Allergy 2013;69:365–371.
12. Werfel T, Asero R, Ballmer-Weber BK, Beyer K, Enrique E, Knulst AC et al. Position paper of the EAACI: food allergy due to immunological cross-reactions with common inhalant allergens. Allergy 2015;70:1079–1090.
13. Bion V, Lockett GA, Soto-Ramírez N, Zhang H, Venter C, Karmaus W et al. Evaluating the efficacy of breastfeeding guidelines on long-term outcomes for allergic disease. Allergy 2016;71:661–670.
14. Castillo-Courtade L, Han S, Lee S, Mian FM, Buck R, Forsythe P. Attenuation of food allergy symptoms following treatment with human milk oligosaccharides in a mouse model. Allergy 2015;70:1091–1102.
15. Otsuka A, Kabashima K. Mast cells and basophils in cutaneous immune responses. Allergy 2014;70:131–140.
16. Schlapbach C, Simon D. Update on skin allergy. Allergy 2014;69:1571–1581.
17. Howell MD, Parker ML, Mustelin T, Ranade K. Past, present, and future for biologic intervention in atopic dermatitis. Allergy 2015;70:887–896.
18. Kono M, Nomura T, Ohguchi Y, Mizuno O, Suzuki S, Tsujiuchi H et al. Comprehensive screening for a complete set of Japanese-population-specific filaggrin gene mutations. Allergy 2014;69:537–540.
19. Boos AC, Hagl B, Schlesinger A, Halm BE, Ballenberger N, Pinarci M et al. Atopic dermatitis, STAT3- and DOCK8-hyper-IgE syndromes differ in IgE-based sensitization pattern. Allergy 2014;69:943–953.
20. Lucae S, Schmid-Grendelmeier P, Wüthrich B, Kraft D, Valenta R, Linhart B. IgE responses to exogenous and endogenous allergens in atopic dermatitis patients under long-term systemic cyclosporine A treatment. Allergy 2015;71:115–118.
21. den Hartog G, van Neerven RJJ, Boot JD, Jansen APH, Savelkoul HFJ. House dust mite-specific IgA2 is associated with protection against eczema in allergic patients. Allergy 2016;71:563–566.
22. Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW et al. The EAACI/GA 2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014;69:868–887.
23. Magerl M, Altrichter S, Borzova E, Giménez-Arnau A, Grattan CEH, Lawlor F et al. The definition, diagnostic testing, and management of chronic inducible urticarias – the EAACI/GA 2LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy 2016;71:780–802.
24. Staubach P, Metz M, Chapman-Rothe N, Sieder C, Bräutigam M, Canvin J et al. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial. Allergy 2016;71:1135–1144.
25. Kolkhir P, Balakirski G, Merk HF, Olisova O, Maurer M. Chronic spontaneous urticaria and internal parasites – a systematic review. Allergy 2015;71:308–322.
26. Spoerri I, Scherer K, Michel S, Link S, Bircher AJ, Heijnen IAFM. Detection of nickel and palladium contact hypersensitivity by a flow cytometric lymphocyte proliferation test. Allergy 2015;70:323–327.
27. Thyssen JP, McFadden JP, Kimber I. The multiple factors affecting the association between atopic dermatitis and contact sensitization. Allergy 2014;69:28–36.
28. Simon D, Aeberhard C, Erdemoglu Y, Simon HU. Th17 cells and tissue remodeling in atopic and contact dermatitis. Allergy 2014;69:125–131.
29. Saarnilehto M, Chapman H, Savinko T, Lindstedt K, Lauerma AI, Koivisto A. Contact sensitizer 2,4-dinitrochlorobenzene is a highly potent human TRPA1 agonist. Allergy 2014;69:1424–1427.
30. Pfaar O, van Twuijver E, Boot JD, Opstelten DJE, Klimek L, van Ree R et al. A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis: results of a phase II study. Allergy 2015;71:99–107.
31. Schmitt J, Stadler E, Küster D, Wüstenberg EG. Medical care and treatment of allergic rhinitis: a population-based cohort study based on routine healthcare utilization data. Allergy 2016;71:850–858.
32. Vuurman EFPM, Vuurman LL, Lutgens I, Kremer B. Allergic rhinitis is a risk factor for traffic safety. Allergy 2014;69:906–912.
33. Deliu M, Belgrave D, Simpson A, Murray CS, Kerry G, Custovic A. Impact of rhinitis on asthma severity in school-age children. Allergy 2014;69:1515–1521.
34. Ando N, Nakamura Y, Ishimaru K, Ogawa H, Okumura K, Shimada S et al. Allergen-specific basophil reactivity exhibits daily variations in seasonal allergic rhinitis. Allergy 2014;70:319–322.
35. Ng CL, Wang DY. Latest developments in allergic rhinitis in Allergy for clinicians and researchers. Allergy 2015;70:1521–1530.
36. Nilsson D, Henmyr V, Halldén C, Säll T, Kull I, Wickman M et al. Replication of genomewide associations with allergic sensitization and allergic rhinitis. Allergy 2014;69:1506–1514.
37. Henmyr V, Lind-Halldén C, Carlberg D, Halldén C, Melén E, Wickman M et al. Characterization of genetic variation in TLR8 in relation to allergic rhinitis. Allergy 2016;71:333–341.
38. Palomares O, Crameri R, Rhyner C. The contribution of biotechnology toward progress in diagnosis, management, and treatment of allergic diseases. Allergy 2014;69:1588–1601.
39. Agache I, Bilò M, Braunstahl G-J, Delgado L, Demoly P, Eigenmann P et al. In vivo diagnosis of allergic diseases-allergen provocation tests. Allergy 2015;70:355–365.
40. Beyer K, Grabenhenrich L, Härtl M, Beder A, Kalb B, Ziegert M et al. Predictive values of component-specific IgE for the outcome of peanut and hazelnut food challenges in children. Allergy 2014;70:90–98.
41. Horimukai K, Hayashi K, Tsumura Y, Nomura I, Narita M, Ohya Y et al. Total serum IgE level influences oral food challenge tests for IgE-mediated food allergies. Allergy 2014;70:334–337.
42. Carrard A, Rizzuti D, Sokollik C. Update on food allergy. Allergy 2015;70:1511–1520.
43. Saleh-Langenberg J, Flokstra-de Blok BMJ, AlAgla N, Kollen BJ, Dubois AEJ. Late reactions in food-allergic children and adolescents after double-blind, placebo-controlled food challenges. Allergy 2016;71:1069–1073.
44. Kong J, Chalcraft K, Mandur TS, Jimenez-Saiz R, Walker TD, Goncharova S et al. Comprehensive metabolomics identifies the alarmin uric acid as a critical signal for the induction of peanut allergy. Allergy 2015;70:495–505.
45. Goldberg A, Stauber T, Peleg O, Hanuka P, Eshayek L, Confino-Cohen R. Medical clowns ease anxiety and pain perceived by children undergoing allergy prick skin tests. Allergy 2014;69:1372–1379.
46. van der Valk JPM, Dubois AE, Gerth van Wijk R, Wichers HJ, de Jong NW. Systematic review on cashew nut allergy. Allergy 2014;69:692–698.
47. Tedeschi A, Kolkhir P, Asero R, Pogorelov D, Olisova O, Kochergin N et al. Chronic urticaria and coagulation: pathophysiological and clinical aspects. Allergy 2014;69:683–691.
48. Papadopoulos NG, Bernstein JA, Demoly P, Dykewicz M, Fokkens W, Hellings PW et al. Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report. Allergy 2015;70:474–494.
49. Smith H, Horney D, Goubet S, Jones C, Raza A, White P et al. Pragmatic randomized controlled trial of a structured allergy intervention for adults with asthma and rhinitis in general practice. Allergy 2014;70:203–211.
50. Klimek L, Hoffmann HJ, Renz H, Demoly P, Werfel T, Matricardi PM et al. Diagnostic test allergens used for in vivo diagnosis of allergic diseases are at risk: a European perspective. Allergy 2015;70:1329–1331.
51. Moreno Benítez F, Espinazo Romeu M, Letrán Camacho A, Mas S, García-Cózar FJ, Tabar AI. Variation in allergen content in sublingual allergen immunotherapy with house dust mites. Allergy 2015;70:1413–1420.
52. Raulf M, Buters J, Chapman M, Cecchi L, de Blay F, Doekes G et al. Monitoring of occupational and environmental aeroallergens – EAACI position paper. Allergy 2014;69:1280–1299.
53. Ciprandi G, Pistorio A, Silvestri M, Rossi GA, Tosca MA. Peanut anaphylaxis: the usefulness of molecular-based allergy diagnostics. Allergy 2014;70:129–130.
54. Schoemaker AA, Sprikkelman AB, Grimshaw KE, Roberts G, Grabenhenrich L, Rosenfeld L et al. Incidence and natural history of challenge-proven cow's milk allergy in European children – EuroPrevall birth cohort. Allergy 2015;70:963–972.
55. Uriarte SA, Sastre J. Clinical relevance of molecular diagnosis in pet allergy. Allergy 2016;71:1066–1068.
56. Schoos AMM, Chawes BLK, Følsgaard NV, Samandari N, Bønnelykke K, Bisgaard H. Disagreement between skin prick test and specific IgE in young children. Allergy 2014;70:41–48.
57. Soares-Weiser K, Takwoingi Y, Panesar SS, Muraro A, Werfel T, Hoffmann-Sommergruber K et al. The diagnosis of food allergy: a systematic review and meta-analysis. Allergy 2013;69:76–86.
58. Wollmann E, Hamsten C, Sibanda E, Ochome M, Focke-Tejkl M, Asarnoj A et al. Natural clinical tolerance to peanut in African patients is caused by poor allergenic activity of peanut IgE. Allergy 2015;70:638–652.
59. Wong KJ, Timbrell V, Xi Y, Upham JW, Collins AM, Davies JM. IgE+ B cells are scarce, but allergen-specific B cells with a memory phenotype circulate in patients with allergic rhinitis. Allergy 2015;70:420–428.
60. Zissler UM, Esser-von Bieren J, Jakwerth CA, Chaker AM, Schmidt-Weber CB. Current and future biomarkers in allergic asthma. Allergy 2016;71:475–494.
61. Hoffmann HJ, Santos AF, Mayorga C, Nopp A, Eberlein B, Ferrer M et al. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease. Allergy 2015;70:1393–1405.
62. Chachi L, Abbassian M, Gavrila A, Alzahrani A, Tliba O, Bradding P et al. Protein phosphatase 5 mediates corticosteroid insensitivity in airway smooth muscle in patients with severe asthma. Allergy 2016, doi: 10.1111/all.13003.
63. Casale TB, Cole J, Beck E, Vogelmeier CF, Willers J, Lassen C et al. CYT003, a TLR9 agonist, in persistent allergic asthma – a randomized placebo-controlled Phase 2b study. Allergy 2015;70:1160–1168.
64. Church MK, Maurer M, Simons FER, Bindslev-Jensen C, van Cauwenberge P, Bousquet J et al. Risk of first-generation H 1-antihistamines: a GA 2LEN position paper. Allergy 2010;65:459–466.
65. Rossbach K, Schaper K, Kloth C, Gutzmer R, Werfel T, Kietzmann M et al. Histamine H4 receptor knockout mice display reduced inflammation in a chronic model of atopic dermatitis. Allergy 2016;71:189–197.
66. Wang M, Han J, Domenico J, Shin YS, Jia Y, Gelfand EW. Combined blockade of the histamine H1 and H4 receptor suppresses peanut-induced intestinal anaphylaxis by regulating dendritic cell function. Allergy 2016;71:1561–1574.
67. Boyman O, Kaegi C, Akdis M, Bavbek S, Bossios A, Chatzipetrou A et al. EAACI IG biologicals task force paper on the use of biologic agents in allergic disorders. Allergy 2015;70:727–754.
68. Boonpiyathad T, Meyer N, Moniuszko M, Sokolowska M, Eljaszewicz A, Wirz OF et al. High-dose bee venom exposure induces similar tolerogenic B-cell responses in allergic patients and healthy beekeepers. Allergy 2016; doi: 10.1111/all.12966.
69. Caramalho I, Melo A, Pedro E, Barbosa MMP, Victorino RMM, Pereira Santos MC et al. Bee venom enhances the differentiation of human regulatory T cells. Allergy 2015;70:1340–1345.
70. Bachmann MF, Kündig TM. Allergen specific immunotherapy: is it vaccination against toxins after all? Allergy 2016, doi: 10.1111/all.12890.
71. Freiberger SN, Zehnder M, Gafvelin G, Gronlund H, Kündig TM, Johansen P. IgG4 but no IgG1 antibody production after intralymphatic immunotherapy with recombinant MAT-Feld1 in human. Allergy 2016;71:1366–1370.
72. Zidarn M, Košnik M, Šilar M, Bajrović N, Korošec P. Sustained effect of grass pollen subcutaneous immunotherapy on suppression of allergen-specific basophil response; a real-life, nonrandomized controlled study. Allergy 2015;70:547–555.
73. Dodev TS, Bowen H, Shamji MH, Bax HJ, Beavil AJ, McDonnell JM et al. Inhibition of allergen-dependent IgE activity by antibodies of the same specificity but different class. Allergy 2015;70:720–724.
74. Gadermaier E, Flicker S, Blatt K, Valent P, Valenta R. Possible therapeutic potential of a recombinant group 2 grass pollen allergen-specific antibody fragment. Allergy 2014;69:261–264.
75. Uermösi C, Zabel F, Manolova V, Bauer M, Beerli RR, Senti G et al. IgG-mediated down-regulation of IgE bound to mast cells: a potential novel mechanism of allergen-specific desensitization. Allergy 2013;69:338–347.
76. Möbs C, Müller J, Rudzio A, Pickert J, Blank S, Jakob T et al. Decline of Ves v 5-specific blocking capacity in wasp venom-allergic patients after stopping allergen immunotherapy. Allergy 2015;70:715–719.
77. Wang L, Yin J, Fadel R, Montagut A, de Beaumont O, Devillier P. House dust mite sublingual immunotherapy is safe and appears to be effective in moderate, persistent asthma. Allergy 2014;69:1181–1188.
78. Devillier P, Fadel R, de Beaumont O. House dust mite sublingual immunotherapy is safe in patients with mild-to-moderate, persistent asthma: a clinical trial. Allergy 2016;71:249–257.
79. Okamoto Y, Fujieda S, Okano M, Yoshida Y, Kakudo S, Masuyama K. House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis. Allergy 2016, doi: 10.1111/all.12996.
80. Maloney J, Durham S, Skoner D, Dahl R, Bufe A, Bernstein D et al. Safety of sublingual immunotherapy Timothy grass tablet in subjects with allergic rhinitis with or without conjunctivitis and history of asthma. Allergy 2015;70:302–309.
81. Nony E, Bouley J, Le Mignon M, Lemoine P, Jain K, Horiot S et al. Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients. Allergy 2015;70:795–804.
82. Senti G, von Moos S, Tay F, Graf N, Johansen P, Kündig TM. Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials. Allergy 2015;70:707–710.
83. Siebeneicher S, Reuter S, Wangorsch A, Krause M, Foetisch K, Heinz A et al. Epicutaneous immunotherapy with a hypoallergenic Bet v 1 suppresses allergic asthma in a murine model. Allergy 2015;70:1559–1568.
84. Klimek L, Uhlig J, Mösges R, Rettig K, Pfaar O. A high polymerized grass pollen extract is efficacious and safe in a randomized double-blind, placebo-controlled study using a novel up-dosing cluster-protocol. Allergy 2014;69:1629–1638.
85. Pfaar O, Demoly P, Gerth van Wijk R, Bonini S, Bousquet J, Canonica GW et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI position paper. Allergy 2014;69:854–867.
86. Pitsios C, Demoly P, Bilò MB, Gerth van Wijk R, Pfaar O, Sturm GJ et al. Clinical contraindications to allergen immunotherapy: an EAACI position paper. Allergy 2015;70:897–909.
87. Abraham I, Alhossan A, Lee CS, Kutbi H, MacDonald K. ‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review. Allergy 2016;71:593–610.
88. Hill DA, Siracusa MC, Ruymann KR, Tait Wojno ED, Artis D, Spergel JM. Omalizumab therapy is associated with reduced circulating basophil populations in asthmatic children. Allergy 2014;69:674–677.
89. Hotze M, Baurecht H, Rodríguez E, Chapman-Rothe N, Ollert M, Fölster-Holst R et al. Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines. Allergy 2013;69:132–135.